8-K filing — Pyxis Oncology, Inc. (PYXS)
Filed: 2026-11-05 AccNo: 0001193125-26-448604 Size: 495 KB Item 2.02: Results of Operations and Financial Condition
Stocks · News reference
Pyxis Oncology Reports Third Quarter 2026 Financial Results
Pyxis Oncology, Inc. announced its financial results for the third quarter ended September 30, 2026, while providing updates on the clinical development of its lead candidate, micvotabart pelidotin (MICVO).
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Pyxis Oncology CEO to Participate in Upcoming Healthcare Conferences
Pyxis Oncology announced that CEO and Chairman Tom Civik will participate in fireside chats at the Guggenheim 3rd Annual Healthcare Innovation Conference and the Stifel 2026 Healthcare Conference.
Pyxis Oncology Announces Late-Breaking Oral Presentation of Micvotabart Pelidotin Data
Pyxis Oncology, Inc. will present Phase 1 monotherapy data for its drug candidate micvotabart pelidotin (MICVO) at the 38th EORTC-NCI-AACR Symposium.
Pyxis Oncology shares are trading lower after the company announced the pricing of its $110 million offering of 36,047,919 shares at $2.90 with common warrants for 49,310,352 shares at a $3.50 exercise price.
Pyxis Oncology Prices $110M Offering Of 36,047,919 Shares At $2.90 With Common Warrants For 49,310,352 Shares At $3.50 Exercise Price
Pyxis Oncology Launches Public Offering Of Common Stock/Pre-Funded Warrants And Warrants To Fund MICVO Phase 3 Development; No Terms Disclosed